News
IONS
52.10
+2.68%
1.36
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust
The Nasdaq plummeted to a one-month low on Wednesday after Tesla and Alphabet disappointed with lackluster earnings. The Dow Jones Industrial Average was down 0.74% and the S&P 500 was down 1.62%. Tesla, Lamb Weston, Blackstone Mortgage Trust were among the biggest losers.
Reuters · 22h ago
BUZZ-U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics
Dow Jones Industrial Average was down 0.78% on Wednesday. The tech-heavy Nasdaq leading declines after lackluster quarterly results from Tesla and Alphabet. The top three S&P 500 percentage gainers were Enphase Energy, AT&T and Check Point Software. FTAI Aviation, Check Point, Sage Therapeutics were up on the day.
Reuters · 23h ago
Leerink upgrades Ionis to outperform, cites Angelman drug
Healthcare Leerink upgrades Ionis to outperform, cites Angelman drug. The investment firm has a price target of $62 for the company's stock. The company's drug candidate ION582 for Angelman syndrome, or AS, is cited as a potential blockbuster.
Seeking Alpha · 1d ago
BUZZ-Leerink Partners upgrade sends Ionis Pharmaceuticals shares higher
Shares of Ionis Pharmaceuticals rise 1.2% to $51.07 in premarket trading. Leerink Partners raises rating on drugmaker to "outperform" from "market perform" Analyst expects upcoming launches of therapies to treat rare genetic disorders.
Reuters · 1d ago
Ionis Pharmaceuticals Raised to Outperform From Market Perform by Leerink Partners
Dow Jones · 1d ago
Ionis Pharmaceuticals Price Target Raised to $62.00/Share From $53.00 by Leerink Partners
Dow Jones · 1d ago
IONIS PHARMACEUTICALS INC <IONS.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $62 FROM $53
Reuters · 1d ago
IONIS PHARMACEUTICALS INC <IONS.O>: LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM
Reuters · 1d ago
Leerink Partners Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $62
Benzinga · 1d ago
Ionis Pharmaceuticals’ ION582: Promising Angelman Syndrome Drug Faces Clinical and Commercial Uncertainties
TipRanks · 1d ago
Ionis Pharmaceuticals Is Maintained at Buy by TD Cowen
Dow Jones · 1d ago
Ionis Pharmaceuticals Price Target Raised to $59.00/Share From $54.00 by TD Cowen
Dow Jones · 1d ago
TD Cowen Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $59
Benzinga · 1d ago
Ionis Pharmaceuticals Is Maintained at Buy by B of A Securities
Dow Jones · 2d ago
Ionis Pharmaceuticals Price Target Raised to $68.00/Share From $67.00 by B of A Securities
Dow Jones · 2d ago
B of A Securities Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $68
Benzinga · 2d ago
IONIS PHARMACEUTICALS INC <IONS.O>: TD COWEN RAISES TARGET PRICE TO $59 FROM $54
Reuters · 2d ago
TD Cowen Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
TipRanks · 2d ago
IONIS PHARMACEUTICALS INC <IONS.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $68 FROM $67
Reuters · 2d ago
Buy Rating on Ionis Pharmaceuticals Backed by Strong Trial Results for Angelman Syndrome Drug
TipRanks · 2d ago
More
Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About IONS
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).